Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $9.56

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus recommendation of “Hold” from the thirteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $9.56.

A number of research firms have recently commented on RAPT. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Thursday, December 26th. Stifel Nicolaus restated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company decreased their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Finally, Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $2.00 in a research report on Monday, November 11th.

RAPT Therapeutics Price Performance

Shares of RAPT opened at $1.11 on Wednesday. The firm has a 50 day simple moving average of $1.26 and a two-hundred day simple moving average of $1.81. RAPT Therapeutics has a one year low of $0.79 and a one year high of $27.35. The company has a market cap of $38.81 million, a P/E ratio of -0.40 and a beta of 0.03.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, analysts expect that RAPT Therapeutics will post -2.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds have recently made changes to their positions in RAPT. JPMorgan Chase & Co. increased its position in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the period. Readystate Asset Management LP bought a new stake in shares of RAPT Therapeutics in the 3rd quarter valued at $36,000. Barclays PLC increased its position in shares of RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares during the period. SG Americas Securities LLC raised its stake in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after buying an additional 42,636 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in RAPT Therapeutics in the second quarter valued at $108,000. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.